Equol has been used in trials studying the treatment of Breast Cancer.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Prasterone | The risk or severity of adverse effects can be increased when Prasterone is combined with Equol. |
| Exemestane | The therapeutic efficacy of Exemestane can be decreased when used in combination with Equol. |
| Hyaluronidase (ovine) | The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Equol. |
| Hyaluronidase (human recombinant) | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Equol. |
| Hyaluronidase | The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Equol. |
| Lenalidomide | Equol may increase the thrombogenic activities of Lenalidomide. |
| Ospemifene | The risk or severity of adverse effects can be increased when Equol is combined with Ospemifene. |
| Ropinirole | Equol may increase the excretion rate of Ropinirole which could result in a lower serum level and potentially a reduction in efficacy. |
| Thalidomide | Equol may increase the thrombogenic activities of Thalidomide. |
| Cetuximab | Equol may increase the thrombogenic activities of Cetuximab. |
| Human immunoglobulin G | Equol may increase the thrombogenic activities of Human immunoglobulin G. |
| Omalizumab | Equol may increase the thrombogenic activities of Omalizumab. |
| Adalimumab | Equol may increase the thrombogenic activities of Adalimumab. |
| Gemtuzumab ozogamicin | Equol may increase the thrombogenic activities of Gemtuzumab ozogamicin. |
| Indium In-111 satumomab pendetide | Equol may increase the thrombogenic activities of Indium In-111 satumomab pendetide. |
| Infliximab | Equol may increase the thrombogenic activities of Infliximab. |
| Trastuzumab | Equol may increase the thrombogenic activities of Trastuzumab. |
| Rituximab | Equol may increase the thrombogenic activities of Rituximab. |
| Basiliximab | Equol may increase the thrombogenic activities of Basiliximab. |
| Muromonab | Equol may increase the thrombogenic activities of Muromonab. |
| Digoxin Immune Fab (Ovine) | Equol may increase the thrombogenic activities of Digoxin Immune Fab (Ovine). |
| Ibritumomab tiuxetan | Equol may increase the thrombogenic activities of Ibritumomab tiuxetan. |
| Tositumomab | Equol may increase the thrombogenic activities of Tositumomab. |
| Alemtuzumab | Equol may increase the thrombogenic activities of Alemtuzumab. |
| Capromab pendetide | Equol may increase the thrombogenic activities of Capromab pendetide. |
| Efalizumab | Equol may increase the thrombogenic activities of Efalizumab. |
| Antithymocyte immunoglobulin (rabbit) | Equol may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit). |
| Natalizumab | Equol may increase the thrombogenic activities of Natalizumab. |
| Palivizumab | Equol may increase the thrombogenic activities of Palivizumab. |
| Daclizumab | Equol may increase the thrombogenic activities of Daclizumab. |
| Bevacizumab | Equol may increase the thrombogenic activities of Bevacizumab. |
| Technetium Tc-99m arcitumomab | Equol may increase the thrombogenic activities of Technetium Tc-99m arcitumomab. |
| Eculizumab | Equol may increase the thrombogenic activities of Eculizumab. |
| Panitumumab | Equol may increase the thrombogenic activities of Panitumumab. |
| Ranibizumab | Equol may increase the thrombogenic activities of Ranibizumab. |
| Galiximab | Equol may increase the thrombogenic activities of Galiximab. |
| Pexelizumab | Equol may increase the thrombogenic activities of Pexelizumab. |
| Afelimomab | Equol may increase the thrombogenic activities of Afelimomab. |
| Epratuzumab | Equol may increase the thrombogenic activities of Epratuzumab. |
| Bectumomab | Equol may increase the thrombogenic activities of Bectumomab. |
| Oregovomab | Equol may increase the thrombogenic activities of Oregovomab. |
| IGN311 | Equol may increase the thrombogenic activities of IGN311. |
| Adecatumumab | Equol may increase the thrombogenic activities of Adecatumumab. |
| Labetuzumab | Equol may increase the thrombogenic activities of Labetuzumab. |
| Matuzumab | Equol may increase the thrombogenic activities of Matuzumab. |
| Fontolizumab | Equol may increase the thrombogenic activities of Fontolizumab. |
| Bavituximab | Equol may increase the thrombogenic activities of Bavituximab. |
| CR002 | Equol may increase the thrombogenic activities of CR002. |
| Rozrolimupab | Equol may increase the thrombogenic activities of Rozrolimupab. |
| Girentuximab | Equol may increase the thrombogenic activities of Girentuximab. |
| Obiltoxaximab | Equol may increase the thrombogenic activities of Obiltoxaximab. |
| XTL-001 | Equol may increase the thrombogenic activities of XTL-001. |
| NAV 1800 | Equol may increase the thrombogenic activities of NAV 1800. |
| Briakinumab | Equol may increase the thrombogenic activities of Briakinumab. |
| Otelixizumab | Equol may increase the thrombogenic activities of Otelixizumab. |
| AMG 108 | Equol may increase the thrombogenic activities of AMG 108. |
| Iratumumab | Equol may increase the thrombogenic activities of Iratumumab. |
| Enokizumab | Equol may increase the thrombogenic activities of Enokizumab. |
| Ramucirumab | Equol may increase the thrombogenic activities of Ramucirumab. |
| Farletuzumab | Equol may increase the thrombogenic activities of Farletuzumab. |
| Veltuzumab | Equol may increase the thrombogenic activities of Veltuzumab. |
| Ustekinumab | Equol may increase the thrombogenic activities of Ustekinumab. |
| Trastuzumab emtansine | Equol may increase the thrombogenic activities of Trastuzumab emtansine. |
| PRO-542 | Equol may increase the thrombogenic activities of PRO-542. |
| TNX-901 | Equol may increase the thrombogenic activities of TNX-901. |
| Inotuzumab ozogamicin | Equol may increase the thrombogenic activities of Inotuzumab ozogamicin. |
| RI 624 | Equol may increase the thrombogenic activities of RI 624. |
| Stamulumab | Equol may increase the thrombogenic activities of MYO-029. |
| CT-011 | Equol may increase the thrombogenic activities of CT-011. |
| Leronlimab | Equol may increase the thrombogenic activities of Leronlimab. |
| Glembatumumab vedotin | Equol may increase the thrombogenic activities of Glembatumumab vedotin. |
| Olaratumab | Equol may increase the thrombogenic activities of Olaratumab. |
| IPH 2101 | Equol may increase the thrombogenic activities of IPH 2101. |
| TB-402 | Equol may increase the thrombogenic activities of TB-402. |
| Caplacizumab | Equol may increase the thrombogenic activities of Caplacizumab. |
| IMC-1C11 | Equol may increase the thrombogenic activities of IMC-1C11. |
| Eldelumab | Equol may increase the thrombogenic activities of Eldelumab. |
| Lumiliximab | Equol may increase the thrombogenic activities of Lumiliximab. |
| Canakinumab | Equol may increase the thrombogenic activities of Canakinumab. |
| Ipilimumab | Equol may increase the thrombogenic activities of Ipilimumab. |
| Nimotuzumab | Equol may increase the thrombogenic activities of Nimotuzumab. |
| Clenoliximab | Equol may increase the thrombogenic activities of Clenoliximab. |
| Tocilizumab | Equol may increase the thrombogenic activities of Tocilizumab. |
| BIIB015 | Equol may increase the thrombogenic activities of BIIB015. |
| Sonepcizumab | Equol may increase the thrombogenic activities of Sonepcizumab. |
| Motavizumab | Equol may increase the thrombogenic activities of Motavizumab. |
| Elotuzumab | Equol may increase the thrombogenic activities of Elotuzumab. |
| AVE9633 | Equol may increase the thrombogenic activities of AVE9633. |
| Carotuximab | Equol may increase the thrombogenic activities of Carotuximab. |
| XmAb 2513 | Equol may increase the thrombogenic activities of XmAb 2513. |
| Coltuximab ravtansine | Equol may increase the thrombogenic activities of Coltuximab ravtansine. |
| Lucatumumab | Equol may increase the thrombogenic activities of Lucatumumab. |
| Pertuzumab | Equol may increase the thrombogenic activities of Pertuzumab. |
| Siplizumab | Equol may increase the thrombogenic activities of Siplizumab. |
| Apolizumab | Equol may increase the thrombogenic activities of Apolizumab. |
| Sibrotuzumab | Equol may increase the thrombogenic activities of Sibrotuzumab. |
| Bivatuzumab | Equol may increase the thrombogenic activities of Bivatuzumab. |
| Lerdelimumab | Equol may increase the thrombogenic activities of Lerdelimumab. |
| Lexatumumab | Equol may increase the thrombogenic activities of Lexatumumab. |
| Reslizumab | Equol may increase the thrombogenic activities of Reslizumab. |